DOMA Perpetual Capital Management, which beneficially owns approximately 6.83% of the outstanding shares of Common Stock of Pacira (PCRX) BioSciences, announced that it intends to nominate three independent director candidates at the Company’s 2026 annual meeting of stockholders. DOMA further asserts the Company’s Board of Directors should pursue an immediate sale of the Company. DOMA considers the current level of Executive Compensation and General Spending to be exorbitant and unmerited and questions whe ...